As mentioned previously, TNFR2 can regulate the expression of PD-L1 in pancreatic cancer; therefore, we hypothesized that TNFR2 blockade would improve PD-L1/PD-1 blockage immunotherapy. Here, CD274 is linked to pancreatic neoplasm.